/Companies

Eye Checkup

London, GB · 2 known investors

Find your way into Eye Checkup

EyeCheckup is an AI-powered eye scanning system that diagnoses retinal diseases, cardiovascular disease, and chronic kidney disease from retinal fundus images. The company serves eye clinics, hospitals, health centers, and aims to increase screening access for the billions of people worldwide who need annual eye exams.

Also known as EyeCheckup

Founders & leadership

RK
Rim KhazinCTO

Board

PD
Prof. Dr. A. Burak BilginAcademic Advisor
DB
Dale BrodskySales Advisor

Investors · 2

Company profile

researched Aug 2026

EyeCheckup is an artificial-intelligence software product that analyzes retinal fundus images and optical coherence tomography (OCT) scans to detect, grade and label retinal abnormalities. The company states the system identifies pathologies associated with more than 20 diseases, including diabetic retinopathy (more-than-mild and vision-threatening grades, plus clinically significant diabetic macular edema suspects), glaucoma (moderate and severe suspect categories), dry and wet age-related macular degeneration including geographic atrophy, retinal vein occlusion, hypertensive retinopathy and pathological myopia. Beyond ophthalmic conditions, the company says the same fundus-image analysis is used to indicate chronic kidney disease (CKD) and cardiovascular disease (CVD).

The software is intended to run alongside a non-mydriatic fundus camera: it analyzes each captured image, marks detected anomalies, and returns results within about three seconds per image, and it also flags invalid captures (clipped, fluorescent, overexposed, too dark, or closed-eye images) within about five seconds so they can be retaken. Outputs include a fundus analysis report and an OCT screening report. The company positions the tool as enabling screening and referral to a specialist without an expert doctor's opinion and without dilating eye drops. For OCT, the company states 11 distinct anomalies are detected, with use cases spanning screening, diagnosis and training.

Latest developments

The company states the project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101073762, and that the product was developed with support from the TÜBİTAK-TEYDEB support programme (project No 7220438), with product responsibility attributed to Ural Telekomünikasyon San. Tic. A.Ş.

▸Full profile — market position, technology, go-to-market, geography

Market position

The company contrasts EyeCheckup with comparable systems by the breadth of its outputs — pathologies linked to more than 20 diseases, plus CVD and CKD indications, rather than a single disease — and by validation across multiple prospective clinical trials and multiple camera types, including handheld hardware. It also emphasizes operation without pupil-dilating eye drops or an expert reader, and positions itself as affordable.

Technology

EyeCheckup applies hybrid deep learning algorithms to two image views per eye — macula-centered and optic-nerve-head-centered — and assigns disease severity levels according to clinical grading standards. The company reports 96% accuracy across three different cameras, including a handheld device, and describes accurate labeling of anomalies on fundus images in addition to disease-level classification. A separate model set analyzes OCT scans for 11 anomaly types. The company states it is the only AI eye-screening software developed in Europe validated in multiple prospective clinical trials, and that its glaucoma model is the only AI compared against a full clinical glaucoma diagnosis (with the corresponding article described as pending). A study of its diabetic retinopathy capability is described as published in Nature's Eye journal and evaluated at Moorfields Eye Hospital on 126,000 diabetes patients.

Go-to-market

The product is integrated with non-mydriatic fundus cameras, and the company maintains a dedicated sales and technical support center in Istanbul alongside a US contact office in San Francisco.

Screening settings that capture retinal images with non-mydriatic or handheld fundus cameras and OCT devices, where patients with suspected eye, cardiovascular or kidney disease can be triaged and referred to specialists without an on-site expert reader.

Geography

Headquarters at 124 City Rd, London, United Kingdom; a US office at Galvanize, 44 Tehama St, San Francisco, California; an R&D center at Akdeniz University Teknokent in Konyaaltı, Antalya, Türkiye; and a sales and technical support center in Levent, Beşiktaş, İstanbul, Türkiye.

Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.

Key figures

latest reported
Diagnostic accuracyJan 202696%
Eye disease pathologies detectedJan 202620 pathologies
OCT anomalies detectedJan 202611 anomalies
Patients in Moorfields Eye Hospital evaluationJan 2026$126K
Per-image analysis timeJan 20263 seconds

Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.

Timeline · 2

launches, deals, and filings
Jan 2026
EU Horizon Europe grant (agreement No 101073762)

The company states the project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101073762.

source ↗

Jan 2026
TÜBİTAK-TEYDEB support programme (project No 7220438)

The product was developed with support from the TÜBİTAK-TEYDEB support programme, project No 7220438, with responsibility for the product attributed to Ural Telekomünikasyon San. Tic. A.Ş.

source ↗

Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.

Companies House · registry record

View on Companies House ↗
Registered name
EYECHECKUP LTD
Company number
15441342
Status
Active
Company type
Private limited company
Incorporated
25 Jan 2024
Registered office
Eyecheckup Ltd, 124 City Road, Lodon, EC1V 2NX
Nature of business (SIC)
32500 — Manufacture of medical and dental instruments and supplies46510 — Wholesale of computers, computer peripheral equipment and software47749 — Retail sale of medical and orthopaedic goods in specialised stores (not incl. hearing aids) n.e.c.72110 — Research and experimental development on biotechnology
Accounts
last made up to 31 Jan 2025 · next due 31 Oct 2026
Confirmation statement
last made up to 14 Jan 2026 · next due 28 Jan 2027

Current officers · 1

  • Rim Khazhin — director, appointed 25 Jan 2024

Source: Companies House public register · retrieved 27 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.

▸Research sources · 1

primary sources listed

1 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Eye Checkup do?
EyeCheckup is an AI system that analyzes retinal fundus images and OCT scans to screen for eye, cardiovascular and kidney disease.
Who are Eye Checkup's investors?
Eye Checkup's investors include Techmine Gsyo, Temasek.
Where is Eye Checkup headquartered?
Eye Checkup is headquartered in London, GB.